Nanotherapeutics Acquires Two Late Stage Clinical Programs For Alzheimer’s Treatment And CDA Disease

Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc. Ramoplanin - an oral antibiotic for the treatment of Clostridium difficile-associated disease (CDAD) - is entering Phase 3 trials...